TNF-Alpha Variant Fusion Molecules for Selective TNFR2 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory diseases lack specificity in targeting TNFR2, leading to unintended activation of TNFR1 and potential off-target effects, and there is a need for more stable and potent TNF-alpha variants that selectively activate TNFR2 to modulate immune responses effectively.
Innovation Solution
Development of TNF-alpha variants with specific mutations, such as D143Y/A145G, that bind with high affinity to TNFR2, are engineered to include a human IgG1 Fc domain with reduced binding to FcγRI, FcγRII, and FcγRIII, and are stabilized by linkers, enhancing serum stability and TNFR2 activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to target TNF-alpha, then anti-inflammatory effects are achieved, but specificity for TNFR2 is lost leading to unintended TNFR1 activation and off-target effects
Solution Approach 1:
The patent applies local quality by introducing specific amino acid mutations (D143Y and A145G) at particular positions in the TNF-alpha variant sequence. These localized changes modify the binding interface to preferentially interact with TNFR2 while reducing affinity for TNFR1, thereby achieving receptor-specific targeting without affecting overall protein structure or function.
Solution Approach 2:
The patent utilizes parameter changes by altering the amino acid sequence parameters of TNF-alpha (specifically positions 143 and 145) to transform its binding characteristics. The mutations change the molecular properties of the protein, enabling selective binding to TNFR2 with high affinity while maintaining stability and solubility, thus resolving the contradiction between specificity and off-target effects.
2Reliability
If TNF-alpha variants with higher affinity for TNFR2 are developed, then TNFR2 activation is improved, but protein stability may be compromised
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at positions 143 and 145 to optimize the balance between binding affinity and protein stability. The D143Y and A145G mutations enhance TNFR2 interaction while the overall protein structure remains stable and soluble, demonstrating that targeted sequence modifications can improve function without compromising structural integrity.
Solution Approach 2:
The patent uses local quality by confining mutations to specific positions (143 and 145) in the TNF-alpha variant sequence that are critical for receptor binding. These localized changes enhance TNFR2 affinity while leaving the rest of the protein structure intact, thereby maintaining overall protein stability and solubility while achieving improved activation efficiency.
3Manufacturing precision
If TNF-alpha variants are engineered to selectively bind TNFR2, then therapeutic precision is improved, but manufacturing complexity increases
Solution Approach 1:
The patent reduces manufacturing complexity by applying local quality - introducing only two specific amino acid mutations (D143Y and A145G) at predetermined positions in the TNF-alpha variant sequence. This focused approach simplifies the engineering process compared to comprehensive protein redesign, while still achieving the desired selective TNFR2 binding and therapeutic precision.
Data Source
AI summary
The present disclosure relates to TNF-alpha variants and TNF-alpha variant fusion molecules and therapeutic uses of such thereof.